Pediatric Endocrinology

Building Your Care Team and Daily Life Management

At a Glance

Children with Laron syndrome benefit from a coordinated team led by a pediatric endocrinologist, with nutrition, genetics, and emotional support. A written school plan, coordinated meals and injections, low-blood-sugar training and accommodations can make daily life safer and more manageable.

Managing Laron syndrome goes beyond medical appointments; it requires building a “home base” of specialists and a supportive environment at school and home. Because your child’s health relies on the careful coordination of hormones, nutrition, and safety, a multidisciplinary team is essential for their success ^[1]^[2].

Building Your Care Team

A pediatric endocrinologist usually leads the team, but several other specialists play vital roles in your child’s development:

Pediatric Endocrinologist: Oversees the mecasermin (IGF-1) therapy, monitors growth velocity, and tracks the timing of puberty ^[1]^[3].
Genetic Counselor: Helps your family understand the GHR mutation, explains how it is passed through the family, and discusses options for future family planning ^[4]^[5].
Pediatric Nutritionist/Registered Dietitian: This is a critical member of the team who helps design a meal and snack schedule that prevents hypoglycemia (low blood sugar) while also managing the risk of truncal obesity ^[6]^[7].
ENT (Ear, Nose, and Throat) Specialist: Conducts screenings for enlarged tonsils or adenoids, which can cause sleep apnea in children taking IGF-1 ^[8]^[9].
Pediatric Psychologist: Assists your child and family in navigating the emotional and social challenges of severe short stature, delayed puberty, and the stress of a chronic medical regimen ^[10]^[11].

Navigating Daily Life and School

Because mecasermin must be given twice daily and coordinated with meals, the school day requires careful planning. Depending on your location and the educational impact of the condition, your child may qualify for formal school accommodations, such as a Section 504 Plan or an Individualized Education Program (IEP) in the United States ^[12]^[13].

Logistics and Safety: Medication administration at school requires a formal prescription, written authorization, and a designated health plan. The school nurse and teachers must be trained to recognize the early signs of hypoglycemia (like shakiness or irritability) and have a written protocol for treating it immediately with fast-acting sugar ^[6]^[14]. If your child has an injection at school, a private, safe space must be provided.
Physical Access: Children with Laron syndrome may have small hands and feet or limited joint mobility ^[15]. School accommodations might include steps for reaching sinks or water fountains, adjustable desks, and smaller-sized chairs to prevent fatigue and support proper posture ^[13].
Psychosocial Support: Research shows that children with severe short stature and delayed puberty may face a higher risk of being bullied or feeling lonely ^[16]^[10]. It is helpful to work with a school counselor early to create an anti-bullying plan and to help teachers understand that your child’s physical size does not reflect their intellectual ability or maturity ^[17]^[10].

Empowering Your Child

As your child grows, their role in managing their condition will also grow. Encouraging them to participate in their care—such as helping to choose their rotating injection sites or picking out healthy snacks—can build confidence ^[18].

Focusing on your child’s strengths, hobbies, and social connections helps ensure that Laron syndrome is just one part of their identity, rather than the defining feature ^[19]^[20]. While the road ahead involves many appointments and careful monitoring, a strong team and a proactive approach can help your child lead a full, active, and healthy life.

Common questions in this guide

Which specialists should be part of my child's Laron syndrome care team?

A pediatric endocrinologist usually leads care, including mecasermin or IGF-1 treatment, growth monitoring, and puberty tracking. A genetic counselor, pediatric dietitian, ear, nose and throat specialist, and pediatric psychologist may also be involved. Each specialist addresses a different part of growth, safety, development, or emotional well-being.

Can my child receive school accommodations for Laron syndrome?

Yes, depending on the child's educational needs and local rules. In the United States, a child may qualify for a Section 504 Plan or an Individualized Education Program, also called an IEP. Possible supports include accessible furniture, help with medication and meals, a private injection space, and an anti-bullying plan.

How should a school prepare for my child's mecasermin injections and low blood sugar?

School staff should have a written prescription or medication authorization, a health plan, and instructions for treating low blood sugar. Staff who work with the child should know early signs such as shakiness or irritability and give fast-acting sugar according to the child's plan. If an injection is needed at school, the child should have a private, safe place.

How can nutrition help prevent low blood sugar in Laron syndrome?

Because mecasermin is given twice a day and coordinated with meals, a pediatric dietitian can help set regular meal and snack times. The diet and dosing plan may need adjustment as the child grows or becomes more active. This planning aims to reduce low blood sugar while also addressing the risk of excess weight around the trunk.

What emotional and social support can help a child with Laron syndrome?

Children may need emotional support for bullying, loneliness, severe short stature, delayed puberty, or the demands of a chronic treatment routine. A pediatric psychologist or school counselor can help the child build coping skills, plan responses to peer questions, and strengthen self-esteem. Celebrating interests and friendships can help Laron syndrome remain only one part of the child's identity.

How should my child's transition to adult endocrine care be planned?

Transition planning should begin before the child leaves pediatric care. The pediatric team can coordinate with an adult endocrinologist, transfer key records, and outline how growth and metabolic monitoring will continue. Ask for a written transition plan so medication, nutrition, and follow-up needs are not lost.

Get notified when new evidence is published on Laron syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study.
Alashwal AA, Al-Fattani A, Ramzan K, et al.
Hormone research in paediatrics 2026; (99(4)):469-479 doi:10.1159/000543047.
PMID: 39657622
2
Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.
Mantovani G, Bastepe M, Monk D, et al.
Nature reviews. Endocrinology 2018; (14(8)):476-500 doi:10.1038/s41574-018-0042-0.
PMID: 29959430
3
Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex® Growth Forum Database Registry.
Bang P, Polak M, Perrot V, et al.
Frontiers in endocrinology 2022; (13()):812568 doi:10.3389/fendo.2022.812568.
PMID: 35250870
4
LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME.
Laron Z
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2015; (21(12)):1395-402 doi:10.4158/EP15939.RA.
PMID: 26401581
5
Reporting a novel growth hormone receptor gene variant in an Iranian consanguineous pedigree with Laron syndrome: a case report.
Bitarafan F, Khodaeian M, Garrousi F, et al.
BMC endocrine disorders 2023; (23(1)):155 doi:10.1186/s12902-023-01388-1.
PMID: 37474955
6
Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry.
Bang P, Polak M, Bossowski A, et al.
The Journal of clinical endocrinology and metabolism 2023; (109(1)):46-56 doi:10.1210/clinem/dgad479.
PMID: 37579214
7
Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.
Petriczko E, Jackowski T, Horodnicka-Józwa A, et al.
Endokrynologia Polska 2019; (70(1)):20-27 doi:10.5603/EP.a2018.0074.
PMID: 30351442
8
Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex® Growth Forum Database Experience.
Bang P, Polak M, Woelfle J, et al.
Hormone research in paediatrics 2015; (83(5)):345-57 doi:10.1159/000371798.
PMID: 25824333
9
Effect of recombinant human insulin-like growth factor 1 therapy in a child with 3-M syndrome-1 with CUL7 gene mutation.
Yang M, Patni N
Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(12)):1609-1612 doi:10.1515/jpem-2020-0278.
PMID: 32924381
10
Growth hormone deficiency, bullying victimization, and associations with treatment status: a pediatric case-control study.
Kocabey Sutcu Z, Caliskan Y, Aytaç Kaplan EH
Journal of pediatric psychology 2026; (51(7)):612-620 doi:10.1093/jpepsy/jsag022.
PMID: 41843717
11
Caregiving burden and special needs of parents in the care of their short-statured children - a qualitative approach.
Lackner L, Quitmann JH, Witt S
Frontiers in endocrinology 2023; (14()):1093983 doi:10.3389/fendo.2023.1093983.
PMID: 37008922
12
Cognitive Functioning in Turner Syndrome: Addressing Deficits Through Academic Accommodation.
Reimann GE, Comis LE, Bernad Perman MM
Women's health reports (New Rochelle, N.Y.) 2020; (1(1)):143-149 doi:10.1089/whr.2019.0019.
PMID: 32617534
13
Exploratory study of the provision of academic and health-related accommodations to transition-age adolescents and emerging adults with spina bifida.
Betz CL, Hudson SM, Skura AL, et al.
Journal of pediatric rehabilitation medicine 2022; (15(4)):593-605 doi:10.3233/PRM-210116.
PMID: 36442216
14
A Systematic Review of School-Based Behavioral Interventions and the Symbolic Labor of Inclusion for Children with Chronic Illness.
Efthymiou E, Katsarou DV, Sofologi M, et al.
Healthcare (Basel, Switzerland) 2025; (13(16)) doi:10.3390/healthcare13161968.
PMID: 40868584
15
A Recurrent Mutation in Growth Hormone Receptor (GHR) Gene Underlying Laron-type Dwarfism in a Pakistani Family.
Shabbir RMK, Nalbant G, Zaman Q, et al.
The Yale journal of biology and medicine 2023; (96(3)):313-325 doi:10.59249/TCAA2040.
PMID: 37780997
16
Impact of idiopathic short stature on children's well-being: a nationwide study of short Danish children.
Juul A, Linglart A, Højby M, et al.
Journal of the Endocrine Society 2026; (10(5)):bvag038 doi:10.1210/jendso/bvag038.
PMID: 41971626
17
Branding of subjects affected with genetic syndromes of severe short stature in developing countries.
Guevara-Aguirre J, Guevara C, Guevara A, Gavilanes AA
BMJ case reports 2020; (13(2)) doi:10.1136/bcr-2019-231737.
PMID: 32041755
18
Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions.
Rutter MM, Crane JL, Babalola F, et al.
Journal of neuromuscular diseases 2026; 22143602261486896 doi:10.1177/22143602261486896.
PMID: 42857968
19
Health-related quality of life in boys with constitutional delay of growth and puberty.
Kariola L, Varimo T, Huopio H, et al.
Frontiers in endocrinology 2022; (13()):1028828 doi:10.3389/fendo.2022.1028828.
PMID: 36518253
20
Functional hypogonadism in adolescence: an overlooked cause of secondary hypogonadism.
Esquivel-Zuniga R, Rogol AD
Endocrine connections 2023; (12(11)).
PMID: 37615381

This page provides general information about coordinating care, school support, and daily management for a child with Laron syndrome; it is not medical advice. Your child's endocrinology team should tailor medication, nutrition, safety, and school plans to their needs.